Supplementary Figure S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20&lt;sup&gt;+&lt;/sup&gt; Non-Hodgkin Lymphomas